US Patent

US9114068 — Treating patients with intravenous ibuprofen

Method of Use · Assigned to Cumberland Pharmaceuticals Inc · Expires 2029-09-30 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating critically ill patients with intravenous ibuprofen to alleviate pain, inflammation, and fever without significantly increasing their blood pressure.

USPTO Abstract

Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1735 — Advil

Patent Metadata

Patent number
US9114068
Jurisdiction
US
Classification
Method of Use
Expires
2029-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Cumberland Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.